Sildenafil Patient Tips

They were told to increase the dose to 100 mg on the next occasion if they experienced a partial response or a lack of response to sildenafil.

What should I do in case of overdose?

Sexual dysfunction has also played a role in reducing patient adherence to the prescribed medication. Consequently, Nurnberg commented to Psychiatric Times, "treatments have been driven more by opinion than by solid data." Nurnberg and colleagues emphasize this concern in their latest study, warning that "without evidence-based data to treat sexual function associated with SRIs in women, clinicians may lack the confidence to manage it effectively, which leaves patients exposed to excess random pharmacology." The investigators employed a design and protocol similar to those in their study with men. The data for women indicated that sildenafil reduced adverse sexual effects, specifically including delayed orgasm responses and inadequate lubrication. Nurnberg commented on the relative sparsity of research on the effect of sildenafil on orgasm function, despite the fact that delayed or unachieved orgasm is "the central factor of SRI antidepressant-associated sexual dysfunction." He attributed this to the FDA-approved indication and marketing focus for male erectile dysfunction and to the more complex measures needed to assess orgasm function in women than sexual arousal in men. In addition, he noted, the initial studies of sildenafil had not shown benefit in women with sexual arousal disorder unrelated to antidepressant medication.

Future Directions

Nevertheless, there was good reason to evaluate the effects of a selective phosphodiesterase type 5 inhibitor such as sildenafil in women experiencing sexual dysfunction from antidepressant medication, according to Nurnberg. The initial studies of sildenafil for women with sexual arousal disorder may not have adequately controlled for hormonal factors or level of sexual interest, or measured efficacy in the varied facets of sexual response. Later, more focused studies yielded favorable results. In addition, Nurnberg noted, nitric oxide synthase isoforms, nitric oxide, and phos- phodiesterase type 5 inhibitors are present in female genital tissue. Phosphodiesterase type 5 inhibitor enhancement of nitric oxide–cyclic guanosine monophosphate signaling occurs in both women and men.

Experimental models for the investigation of female sexual function and dysfunction

Studying Drug Treatment of Adverse Drug EffectWomen in the Nurnberg study had to have reported good sexual interest and activity before the onset of depression and antidepressant treatment. Their episodes of sexual dysfunction had to be associated with antidepressant treatment and needed to have remitted with improvement of depression and discontinuation of medication. Baseline endocrine values were obtained in these women to later analyze for possible correlations with treatment response. This analysis indicated that women whose sexual function improved after receiving sildenafil or placebo had higher mean levels of free testosterone and thyroxine. Ninety-eight women of 145 screened were sildenafil oral jelly 100mg lovegra randomized to receive either sildenafil in a 50-mg starting dosage or matching placebo. The nine patients, all of whom had experienced either anorgasmia or delayed orgasm with or without associated

disturbances, reported significant reversal of sexual dysfunction, usually with the first dose of 50 mg of sildenafil.

Further information

Treatment of antidepressant-associated sexual dysfunction with sildenafil: a randomized controlled trial. Rudkin L, Taylor MJ, Hawton K. Strategies for managing sexual dysfunction induced by antidepressant medication. In an open study, sildenafil (Viagra) was prescribed for nine women outpatients who reported sexual dysfunction induced by antidepressant medication, primarily selective serotonin reuptake inhibitors. A 50 mg dose of sildenafil was prescribed, and patients were instructed to take it approximately one hour before sexual activity. Sildenafil is used to treat erectile dysfunction (ED) in men or pulmonary

• Sildenafil is not a universal solution for female sexual desire disorders.
• Monitored clinical trials are ongoing to assess safety for women.
• Self-medicating with sildenafil can lead to adverse effects.
• It is essential to get a comprehensive diagnosis before use.

arterial hypertension (PAH) in both men and women, depending on the brand. Viagra and Vybrique are used for ED and Revatio is used for PAH.

• Sildenafil's effect duration in women may range from 4 to 6 hours.
• It may help women experiencing low libido linked to blood flow issues.
• The drug’s efficacy in women is less predictable than in men.
• Female sexual dysfunction has multiple causes beyond blood flow.

Sildenafil works by blocking the action of an enzyme called cGMP-specific phosphodiesterase type-5 (PDE-5).

• Some studies investigate sildenafil’s impact on vaginal blood flow.
• Psychological factors also significantly influence female sexual response.
• Not all women will experience improved sexual function with sildenafil.
• Sexual therapy remains an important treatment option.

This enzyme breaks down cGMP, a substance that induces smooth muscles to relax.

Blocking PDE-5 means increased levels of cGMP within the smooth muscles

Statistical Analysis

During double-blind visits, patients completed 1-month recall SFQ28 and FSDS-DAO surveys. Within 24 hours of a sexual event, participants recorded data in an electronic diary. Participants’ response to the question “Did you consider sexual activity satisfactory for you?” in the electronic diary after a sexual event was the secondary outcome of the analysis, measured as the changes in the number and proportion of satisfying events from baseline to week 12. There were 200 participants included in the final analysis, 101 of whom received sildenafil cream and 99 placebo cream. Of participants, 99 and 94, respectively, were in the intention-to-treat (ITT) analysis and 90 and 84, respectively, completed all study visits.1 When measuring outcomes based on the SFQ28 Arousal Sensation domain, increased efficacy was reported for the sildenafil cream group vs the placebo cream group.

Increased genital blood flow

However, statistically significant improvements were not observed for either coprimary endpoint during the double-blind period, nor were the number of satisfying events improved. In the ITT population, patients in the sildenafil cream group had significantly improved SFQ28 Desire domain scores at week 8, which was considered an exploratory endpoint. Women with female sexual arousal disorder with concomitant orgasmic dysfunction had lessened treatment benefits at week 12 vs those with other sexual dysfunction diagnoses.1 The largest 12-week improvements in sexual dysfunction from sildenafil cream were observed among women with only female sexual desire disorder as their sexual dysfunction. These patients had significant improvements in the SFQ28 Arousal Sensation domain, SFQ28 Desire domain, and SFQ28 Orgasm domain vs placebo users. These results indicated improved outcomes from sildenafil cream among women with female sexual arousal disorder.

Curr. Psychiatry Rep.

Investigators recommended removing the restrictions to enroll sexual partners in future studies to evaluate a more diverse study population.1 Johnson I, Thurman A, Cornell K, et al. Preliminary efficacy of topical sildenafil cream for the treatment of female sexual arousal disorder: A randomized controlled trial. Potential first-in-category therapy for female sexual arousal disorder. Sildenafil (Viagra, Revatio) reduced antidepressant-associated sexual dysfunction in women in a randomized controlled trial, which investigators characterize as the first conducted in women with this adverse drug effect. The study, recently published in JAMA, was conducted by George Nurnberg, MD, of the department of psychiatry, University of New Mexico, and colleagues.1 This group's 2003 study, also published in JAMA, demonstrated sildenafil's benefit in men with this complaint.2 That study was a departure from the anecdotal or open-label reports that served as an evidence base for a myriad of proposed remedies.3 Although the association between sexual dysfunction and antidepressant therapy has been recognized since the introduction of tricyclics, the incidence of this adverse effect has increased since the advent of serotonin reuptake inhibitors (SRIs). which promotes muscle relaxation and vasodilation (a widening of blood vessels).

High levels of PDE-5 are found in the penis, lungs, and retina.

• Common side effects in women may include dizziness and nasal congestion.
• Women should avoid it if they are pregnant or breastfeeding.
• Combining sildenafil with nitrates can cause dangerous drops in blood pressure.
• It is important to follow prescribed dosages strictly.

PDE-5 is also found throughout the body within the smooth muscle cells of the blood vessels and muscles.

What special precautions should I follow?

They were instructed to take the study medication approximately 1 to 2 hours before anticipated sexual activity but not more than once daily. They were asked to attempt to have sexual activity twice weekly, but not less than once weekly throughout the 8-week trial. Treatment efficacy was measured with 4 validated instruments. The primary outcome measure was the mean improvement on the Clinical Global Impression Scale (CGI) adapted for sexual function. Secondary outcome instruments were the Sexual Function Questionnaire, the Arizona Sexual Experience scale–female version, and the University of New Mexico Sexual Function Inventory–female version.

Mohamed Alhefnawy1*, Abdulla Esawy2, Mohamed Abdelazeem1, Mohamed Elnamoury3, Ahmed Eissa4, Ahmed Zoair4, Ahmed Ghaith4, Ayman Hagras4 and Khaled Almekaty4

Patients maintained logs that were reviewed for the frequency and percentage of successful intercourse attempts and the number of satisfactory attempts at orgasm. In the intention-to-treat analysis, women receiving sildenafil had a statistically significant higher mean score improvement from baseline of 1.9 on the CGI than the 1.1 mean improved score for those receiving placebo. In the secondary outcome measures, sildenafil was associated with greater improvement on scores in the domain of orgasm function, including the ability to reach orgasm and to experience orgasm satisfaction. The investigators proclaimed this study important "not only because women experience major depressive disorder at nearly double the rate of men and because they experience greater resulting sexual dysfunction than men, but also because it establishes that selective phosphodiesterase type 5 inhibitors are effective in both sexes for this purpose." In later discussion, Nurnberg added, "the issue is keeping patients compliant with a medication by actively treating a side effect." Although acknowledging that clinical options include switching adversely affected patients from an SRI to an antidepressant having less incidence of sexual dysfunction, Nurnberg cautioned against discontinuing an effective agent with side effects and substituting another agent, which may or may not be as effective. Instead, he recommended that clinicians "encourage the patient not to stop the medication but to call to discuss which option would be useful-including waiting for it to go away." SildenÂafil treatment of women with antidepressant-asso-ciated sexual dysfunction: a randomized controlled trial.